Zhijian Xiao

机构：Chinese Academy of Medical Sciences & Peking Union Medical College, Harbin Institute of Technology, Tianjin Economic-Technological Development Area, Institute of Hematology & Blood Diseases Hospital · ORCID：0000-0002-1099-4489

发表论文 269 篇 · 总被引 2849 次 · h-index 31

代表论文

• A comparative analysis of clinical outcomes in hematological patients afflicted with bacteremia attributable to carbapenem-resistant Klebsiella pneumoniae versus Escherichia coli (2025 · Frontiers in Cellular and Infection Microbiology · 被引 8)
• Subgroup analyses from the randomized, Phase 3 VERONA study of venetoclax with azacitidine (Ven+Aza) versus placebo with azacitidine (Pbo+Aza) in patients with treatment-naïve, intermediate and higher-risk Myelodysplastic Syndromes (HR MDS) (2025 · Blood · 被引 6)
• Comparative analysis of patients’ characteristics, treatment, and survival outcomes in CLL from China and the United States (2025 · The Oncologist · 被引 5)
• China Expert consensus on the application of metagenomic next-generation sequencing for the etiological diagnosis of infections in hematological disorders (2024) (2025 · Blood Science · 被引 3)
• A correlation of ineffective erythropoiesis and dysregulated signaling pathways in myelodysplastic syndromes/neoplasms (2025 · Experimental Hematology and Oncology · 被引 3)
• Sabotaged Integral HSC Heterogeneity Underlies Essential Thrombocythemia Development (2025 · Advanced Science · 被引 1)